NO981430D0 - Truncated glial cell-derived neurotrophic factor - Google Patents
Truncated glial cell-derived neurotrophic factorInfo
- Publication number
- NO981430D0 NO981430D0 NO981430A NO981430A NO981430D0 NO 981430 D0 NO981430 D0 NO 981430D0 NO 981430 A NO981430 A NO 981430A NO 981430 A NO981430 A NO 981430A NO 981430 D0 NO981430 D0 NO 981430D0
- Authority
- NO
- Norway
- Prior art keywords
- neurotrophic factor
- derived neurotrophic
- glial cell
- truncated
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF proteins by recombinant genetic engineering techniques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/535,681 US6184200B1 (en) | 1995-09-28 | 1995-09-28 | Truncated glial cell line-derived neurotrophic factor |
PCT/US1996/014915 WO1997011964A1 (en) | 1995-09-28 | 1996-09-16 | Truncated glial cell line-derived neurotrophic factor |
Publications (3)
Publication Number | Publication Date |
---|---|
NO981430D0 true NO981430D0 (en) | 1998-03-30 |
NO981430L NO981430L (en) | 1998-03-30 |
NO322521B1 NO322521B1 (en) | 2006-10-16 |
Family
ID=24135310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19981430A NO322521B1 (en) | 1995-09-28 | 1998-03-30 | Abbreviated glial cell line derived neurotrophic factor (GDNF) protein product, plynucleotide encoding it, vector comprising the polynucleotide, use of the GDNF protein product for drug preparation, use of said polynucleotide for drug preparation, use of transformed cell polynucleotide preparation drug, prokaryotic or eukaryotic host cell transfected with the polynucleotide, method of producing truncated GDNF protein, pharmaceutical composition comprising it and method of preparation of the preparation. |
Country Status (25)
Country | Link |
---|---|
US (5) | US6184200B1 (en) |
EP (1) | EP0920448B1 (en) |
JP (3) | JP4153036B2 (en) |
KR (1) | KR100334739B1 (en) |
CN (1) | CN1283659C (en) |
AT (1) | ATE314389T1 (en) |
AU (1) | AU707528B2 (en) |
CA (1) | CA2232749C (en) |
CZ (1) | CZ297326B6 (en) |
DE (1) | DE69635675T2 (en) |
DK (1) | DK0920448T3 (en) |
EA (1) | EA001204B1 (en) |
ES (1) | ES2255713T3 (en) |
HK (1) | HK1021823A1 (en) |
HU (1) | HU226220B1 (en) |
IL (6) | IL123761A (en) |
MX (1) | MX9802278A (en) |
NO (1) | NO322521B1 (en) |
NZ (1) | NZ318697A (en) |
SI (1) | SI0920448T1 (en) |
SK (1) | SK288094B6 (en) |
TW (1) | TW570926B (en) |
UA (1) | UA66339C2 (en) |
WO (1) | WO1997011964A1 (en) |
ZA (1) | ZA968087B (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
DE19816186A1 (en) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-encoding DNA, parts thereof and GDNF variants |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6507788B1 (en) * | 1999-02-25 | 2003-01-14 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function |
US6897061B1 (en) | 2000-06-16 | 2005-05-24 | Spinal Cord Society | Transdifferentiation of glial cells |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US7245117B1 (en) | 2004-11-01 | 2007-07-17 | Cardiomems, Inc. | Communicating with implanted wireless sensor |
AU2004283053A1 (en) | 2003-10-20 | 2005-05-06 | Nsgene A/S | In vivo gene therapy of Parkinson's Disease |
CN1897977A (en) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | In vivo gene therapy of parkinson's disease |
EP1784203B1 (en) | 2004-08-19 | 2010-06-30 | Biogen Idec MA Inc. | Refolding transforming growth factor beta family proteins |
TWI501774B (en) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | Treatments for neurological disorders |
PL2054074T3 (en) * | 2006-08-04 | 2015-03-31 | Prolong Pharmaceuticals Llc | Modified erythropoietin |
US20090069230A1 (en) * | 2007-02-12 | 2009-03-12 | The Research Foundation Of State University Of New York | Gdnf-derived peptides |
EP2142205B1 (en) | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow |
US8446454B2 (en) | 2007-05-21 | 2013-05-21 | Polycom, Inc. | Dynamic adaption of a continuous presence videoconferencing layout based on video content |
FI20070808A0 (en) * | 2007-10-25 | 2007-10-25 | Mart Saarma | Split variants of GDNF and uses thereof |
UA112981C2 (en) * | 2011-04-11 | 2016-11-25 | Елі Ліллі Енд Компані | OPTION OF HUMAN GDNF |
EP2968462B1 (en) | 2013-03-15 | 2020-12-23 | The Jackson Laboratory | Methods for promoting wound healing and hair growth |
RU2561050C2 (en) * | 2013-08-28 | 2015-08-20 | Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) | Application of protein yb-1 and its fragments for production of medications in treatment of alzheimer's disease |
CA3043179A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Gdnf fusion polypeptides and methods of use thereof |
EP4076499A4 (en) * | 2019-12-19 | 2023-11-01 | Transfert Plus Societe en Commandite | Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
JP2989002B2 (en) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | Chemically modified granulocyte colony stimulating factor |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US5229500A (en) | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
CA1332433C (en) | 1989-09-29 | 1994-10-11 | Robert L. Sutherland | Ski structure and binding therefor |
DE69033584T2 (en) | 1989-10-16 | 2001-03-08 | Amgen Inc | Stem cell factor |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
US5202428A (en) | 1990-06-20 | 1993-04-13 | The Salk Institute For Biological Studies | DNA encoding neurotropic growth factor |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
ES2225819T3 (en) | 1991-09-20 | 2005-03-16 | Amgen Inc. | GLIAL ORIGIN NEUROTROPHIC FACTOR. |
AU1443095A (en) | 1993-12-22 | 1995-07-10 | University Of Medicine And Dentistry Of New Jersey | Novel nucleic acid sequences isolated from glial cells |
FR2717824B1 (en) | 1994-03-25 | 1996-04-26 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
US5733875A (en) * | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
US5837681A (en) * | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
-
1995
- 1995-09-28 US US08/535,681 patent/US6184200B1/en not_active Expired - Lifetime
-
1996
- 1996-09-16 AU AU70746/96A patent/AU707528B2/en not_active Ceased
- 1996-09-16 CZ CZ0088298A patent/CZ297326B6/en not_active IP Right Cessation
- 1996-09-16 SK SK389-98A patent/SK288094B6/en not_active IP Right Cessation
- 1996-09-16 DE DE69635675T patent/DE69635675T2/en not_active Expired - Lifetime
- 1996-09-16 AT AT96931618T patent/ATE314389T1/en active
- 1996-09-16 IL IL12376196A patent/IL123761A/en not_active IP Right Cessation
- 1996-09-16 EA EA199800301A patent/EA001204B1/en not_active IP Right Cessation
- 1996-09-16 UA UA98031545A patent/UA66339C2/en unknown
- 1996-09-16 IL IL14448896A patent/IL144488A0/en active IP Right Grant
- 1996-09-16 ES ES96931618T patent/ES2255713T3/en not_active Expired - Lifetime
- 1996-09-16 KR KR1019980702293A patent/KR100334739B1/en not_active IP Right Cessation
- 1996-09-16 NZ NZ318697A patent/NZ318697A/en not_active IP Right Cessation
- 1996-09-16 EP EP96931618A patent/EP0920448B1/en not_active Expired - Lifetime
- 1996-09-16 SI SI9630726T patent/SI0920448T1/en unknown
- 1996-09-16 IL IL14401896A patent/IL144018A0/en unknown
- 1996-09-16 DK DK96931618T patent/DK0920448T3/en active
- 1996-09-16 JP JP51349497A patent/JP4153036B2/en not_active Expired - Fee Related
- 1996-09-16 HU HU9802262A patent/HU226220B1/en not_active IP Right Cessation
- 1996-09-16 CN CNB961972335A patent/CN1283659C/en not_active Expired - Fee Related
- 1996-09-16 WO PCT/US1996/014915 patent/WO1997011964A1/en active Application Filing
- 1996-09-16 CA CA002232749A patent/CA2232749C/en not_active Expired - Fee Related
- 1996-09-26 ZA ZA968087A patent/ZA968087B/en unknown
- 1996-09-26 TW TW085111819A patent/TW570926B/en not_active IP Right Cessation
-
1998
- 1998-03-23 MX MX9802278A patent/MX9802278A/en active IP Right Grant
- 1998-03-30 NO NO19981430A patent/NO322521B1/en not_active IP Right Cessation
-
1999
- 1999-12-09 HK HK99105788A patent/HK1021823A1/en not_active IP Right Cessation
-
2001
- 2001-06-26 IL IL144018A patent/IL144018A/en not_active IP Right Cessation
- 2001-07-23 IL IL144488A patent/IL144488A/en not_active IP Right Cessation
-
2004
- 2004-01-07 US US10/753,592 patent/US7390781B2/en not_active Expired - Fee Related
- 2004-05-25 US US10/853,930 patent/US20040214776A1/en not_active Abandoned
- 2004-05-26 US US10/855,820 patent/US7611865B2/en not_active Expired - Fee Related
-
2007
- 2007-09-05 JP JP2007229870A patent/JP4909843B2/en not_active Expired - Fee Related
-
2010
- 2010-06-21 JP JP2010140665A patent/JP5241037B2/en not_active Expired - Fee Related
-
2011
- 2011-06-23 US US13/167,419 patent/US20110251267A1/en not_active Abandoned
-
2012
- 2012-02-27 IL IL218336A patent/IL218336A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO981430L (en) | Truncated glial cell-derived neurotrophic factor | |
DK1210411T3 (en) | Compositions and Methods for Improved Cell Culture | |
DK1428878T3 (en) | Process for the production and purification of erythropoietin | |
WO2002029083A3 (en) | Industrial-scale serum-free production of recombinant proteins in mammalian cells | |
UA81398C2 (en) | Keratinocytes which may be used as biologically active substances for the treatment of wounds | |
PT720482E (en) | PROSPHOSINE AND CYTOKINE DERIVATIVES USED AS AGENTS | |
DE69739996D1 (en) | Methods and compositions for the production of polypeptides | |
AR020735A1 (en) | A PROCEDURE FOR OBTAINING A GLUCOSYLED POLYPEPTIDE FROM EUCARIOTIC CELLS | |
TW200505939A (en) | Process for production of cyclic peptides | |
ATE437951T1 (en) | INTRACELLULAR PRODUCTION OF SHORTENED HEPATITIS C-POLYPEPTIDE E2 | |
ATE449175T1 (en) | BACTERIAL PRODUCTION OF INTERFERON-BETA POLYPEPTIDES | |
DE69637844D1 (en) | NEW TGF-BETA-SIMILAR CYTOKIN | |
DK1137808T3 (en) | Process for producing recombinant cells | |
HN2000000264A (en) | 2,4-DIAMINO-PYRIMIDINE COMPOSITE USEFUL AS IMMUNITY SUPPRESSORS | |
WO2005026375A3 (en) | Recombinant carrier molecule for expression, delivery and purification of target polypeptides | |
IL126221A0 (en) | Scf analog compositions and methods | |
GB2322132B (en) | Keratinocyte growth factor-2 products | |
ATE246935T1 (en) | CNS NEUROREGENERATIVE COMPOSITIONS AND USES THEREOF | |
DK0977859T3 (en) | The neurotrophic factor NNT-1 | |
WO2002068668A3 (en) | Compositions and methods for production cell culture | |
EP1440085B8 (en) | Transient immortalization of cells by oncogenic proteins or telomerase | |
ATE470700T1 (en) | BACILLUS CELL FOR PRODUCING PROTEINS | |
ECSP972224A (en) | IMMORTALIZED CELLS FOR VIRUS CULTIVATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |